Merck CEO Robert Davis has been landing deals “with urgency” over the last few years in an effort to shore up the pipeline ahead of Keytruda’s upcoming patent cliff. But make no mistake: The company ...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.